Amgen gets a lift in deal with Takeda

Article Abstract:

A marketing agreement has been established between American biotechnology firm Amgen Inc. and Japanese pharmaceutical firm Takeda Pharmaceutical Company Ltd. The deal is worth up to $1.19 bil plus royalties, and provides Takeda with marketing rights throughout Asia to 13 of Amgen's products currently in development. Takeda will also purchase Amgen KK, Amgen's Japanese subsidiary.

Acquisitions & mergers, Parent-to-subsidiary activities, Subsidiary-to-parent activities, United States, Japan, Mergers, acquisitions and divestments, Company acquisition/merger, Amgen Inc., AMGN, Subsidiaries, divisions and units, Takeda Pharmaceutical Company Ltd.

---

Roche results jump, outpacing industry

Article Abstract:

Roche Holding Ltd. of Switzerland posted a stellar 33 percent rise in 2006 net profit to 7.88 billion Francs ($6.35 billion) from 5.92 billion Francs last year. Sales increased by 18 percent to 42.04 billion Francs. Strong revenues were due to popular sales of blockbuster cancer drugs as well as Tamiflu the flu medication.

Sales, profits & dividends, Company sales and earnings, Company earnings/profit, Company overview, Financial report

---

Roche signs vaccine deal with France's Transgene: Swiss drug firm gets access to program for cervical cancer

Article Abstract:

Roche Holding Ltd. and Transgene S.A. have signed an agreement allowing Roche to research and market a vaccine for cervical cancer. The $293 mil deal provides Roche with access to the therapeutic vaccine program at Transgene, which includes research on other diseases involving the human papilloma virus.

Science & research, Drugs, Research, Biotechnology industry, Biotechnology industries, France, Drug therapy, Cervical cancer, Cancer vaccines, Research agreements, Papillomavirus vaccines, Transgene S.A.

Similar abstracts:

• Abstracts: Portfolio rebalancing model with transaction costs based on fuzzy decision theory. Rating technical attributes in fuzzy QFD by integrating fuzzy weighted average method and fuzzy expected value operator
• Abstracts: Portfolio rebalancing model with transaction costs based on fuzzy decision theory. part 2 Indeterminacy in portfolio selection
• Abstracts: SAP warns on costs of a simpler product. SAP's results calm concerns among investors over strategy. SAP trails nimble start-ups as software market matures
• Abstracts: Chevron reimages Town Pantry brand. Ads take B.C. forest industry to task
• Abstracts: Railway unions strike in France and Germany. French, German strikes set to disrupt rail service. French jobless rate falls to 8.4 percent but data reliability is questioned

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.